Latest News and Press Releases
Want to stay updated on the latest news?
-
Austin, July 10, 2025 (GLOBE NEWSWIRE) -- Drone Photography Services Market Size & Growth Insights: According to the SNS Insider Report, “The Drone Photography Services Market was valued at USD...
-
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Eos Energy Enterprises, Inc. (“Eos” or the “Company”) (NASDAQ: EOSE). Such investors are...
-
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. (“Sarepta” or the “Company”) (NASDAQ: SRPT). Such...
-
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caleres, Inc. - CAL
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Caleres, Inc. (“Caleres” or the “Company”) (NYSE: CAL). Such investors are advised to...
-
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY). Such investors are advised to contact...
-
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Neogen Corporation (“Neogen” or the “Company”) (NASDAQ: NEOG). Such investors are advised...
-
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS)....
-
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Broadmark Realty Capital Inc. (“Broadmark” or the “Company”) (NYSE: BRMK). ...
-
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT). Such...
-
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR). Such investors are...